[{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Arbutus Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Arbutus Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Arbutus Biopharma"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"||Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"||Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"||Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"||Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"||Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ BeiGene","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ BeiGene"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Vebicorvir","moa":"Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0.54000000000000004,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.54000000000000004,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ BeiGene","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ BeiGene"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"||Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"||Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Assembly Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Entecavir","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arbutus Biopharma \/ Assembly Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Biopharma \/ Assembly Biosciences"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Assembly Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Entecavir","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arbutus Biopharma \/ Assembly Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Biopharma \/ Assembly Biosciences"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATI-2173","moa":"||Hepatitis B virus Polymerase (HBV P)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Antios Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Antios Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"ATI-2173","moa":"||Hepatitis B virus Polymerase (HBV P)","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Assembly Biosciences \/ Antios Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Assembly Biosciences \/ Antios Therapeutics"}]
Find Clinical Drug Pipeline Developments & Deals for Vebicorvir
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
